

**UNITED STATES OF AMERICA
BEFORE THE FEDERAL TRADE COMMISSION**

In the Matter of)	
)	
Hikma Pharmaceuticals PLC,)	
 a corporation,)	
)	
Custopharm, Inc.,)	
 a corporation,)	
)	File No. 221-0002
Water Street Healthcare Partners, LLC,)	
 a limited liability company,)	
)	
Water Street Healthcare Partners III, L.P.,)	
 a limited partnership,)	
)	
Water Street Healthcare Partners IV, L.P.,)	
 a limited partnership, and)	
)	
Long Grove Pharmaceuticals, LLC,)	
 a limited liability company.)	

AGREEMENT CONTAINING CONSENT ORDERS

The Federal Trade Commission (“Commission”) initiated an investigation of the proposed acquisition by Respondent Hikma Pharmaceuticals PLC of the voting securities of Respondent Custopharm, Inc., a subsidiary of Respondent Water Street Healthcare Partners, LLC. The Commission’s Bureau of Competition has prepared a draft administrative complaint (“Draft Complaint”). The Bureau of Competition and Proposed Respondents enter into this Agreement Containing Consent Orders (“Consent Agreement”) to retain certain assets and to provide for other relief to resolve the allegations in the Draft Complaint through a proposed Decision and Order, both of which are attached, to present to the Commission.

IT IS HEREBY AGREED by and between Proposed Respondents, by their duly authorized officers and attorneys, and counsel for the Commission that:

1. Proposed Respondent Hikma Pharmaceuticals PLC is a corporation organized, existing, and doing business under, and by virtue of, the laws of the United Kingdom with its executive offices and principal place of business located at 1 New Burlington Place, London, W1S 2HR, United Kingdom.
2. Proposed Respondent Custopharm, Inc. is a corporation organized, existing, and doing business under, and by virtue of, the laws of the State of Texas with its

executive offices and principal place of business located at 2325 Camino Vida Roble, Carlsbad, California, 92011.

3. Proposed Respondent Water Street Healthcare Partners, LLC is a limited liability company organized, existing, and doing business under, and by virtue of, the laws of the State of Delaware with its executive offices and principal place of business located at 444 West Lake Street, Suite 1800, Chicago, Illinois, 60606.
4. Proposed Respondent Water Street Healthcare Partners III, L.P. (Fund III) is a limited partnership organized, existing, and doing business under, and by virtue of, the laws of the State of Delaware with its executive offices and principal place of business located at 444 West Lake Street, Suite 1800, Chicago, Illinois, 60606.
5. Proposed Respondent Water Street Healthcare Partners IV, L.P. (Fund IV) is a limited partnership organized, existing, and doing business under, and by virtue of, the laws of the State of Delaware with its executive offices and principal place of business located at 444 West Lake Street, Suite 1800, Chicago, Illinois, 60606.
6. Proposed Respondent Long Grove Pharmaceuticals, LLC is a limited liability company organized, existing, and doing business under, and by virtue of, the laws of the State of Delaware with its executive offices and principal place of business located at 9450 W. Bryn Mawr Avenue, Suite 200, Rosemont, Illinois, 60018.
7. Proposed Respondents admit all the jurisdictional facts set forth in the Draft Complaint.
8. Proposed Respondents waive:
 - a. any further procedural steps;
 - b. the requirement that the Decision and Order contain a statement of findings of fact and conclusions of law;
 - c. all rights to seek judicial review or otherwise to challenge or contest the validity of the Decision and Order entered pursuant to this Consent Agreement; and
 - d. any claim under the Equal Access to Justice Act.
9. This Consent Agreement is for settlement purposes only and does not constitute an admission by Proposed Respondents that the law has been violated as alleged in the Draft Complaint, or that the facts as alleged in the Draft Complaint, other than jurisdictional facts, are true.
10. Proposed Respondents shall submit an initial compliance report, pursuant to Commission Rule 2.33, 16 C.F.R. § 2.33, no later than 30 days after the date on which Proposed Respondents execute this Consent Agreement and subsequent compliance reports every 30 days thereafter until the Decision and Order becomes

final. After the Decision and Order becomes final, the reporting obligations contained in the Decision and Order shall control and the reporting obligations under this Consent Agreement shall cease. The compliance reports shall set forth in detail the manner in which Proposed Respondents have complied, have prepared to comply, are complying, and will comply with the Consent Agreement and the Decision and Order. Proposed Respondents shall provide sufficient information and documentation to enable the Commission to determine independently whether Proposed Respondents are in compliance with the Consent Agreement and the Decision and Order.

11. Each compliance report submitted pursuant to Paragraph 10 above shall be verified in the manner set forth in 28 U.S.C. § 1746 by the Chief Executive Officer or another officer or employee specifically authorized to perform this function. Commission Rule 2.41(a), 16 C.F.R. § 2.41(a), requires that the Commission receive an original and one copy of each compliance report. Proposed Respondents shall electronically file an original of each compliance report with the Secretary of the Commission at ElectronicFilings@ftc.gov, and with the Compliance Division at bccompliance@ftc.gov. In addition, Proposed Respondents shall provide a copy of each compliance report to the Monitor, if one has been appointed pursuant to the Decision and Order.
12. This Consent Agreement, and any compliance reports filed pursuant to this Consent Agreement, shall not become part of the public record of the proceeding unless and until the Commission accepts the Consent Agreement. If the Commission accepts this Consent Agreement, the Commission will place it, together with the Complaint and the proposed Decision and Order, an explanation of the provisions of the proposed Decision and Order, and any other information that may help interested persons understand the orders on the public record for the receipt of comments for 30 days.
13. Because there may be interim competitive harm, the Commission may issue and serve its Complaint (in such form as circumstances may require) in this matter at any time after it accepts the Consent Agreement for public comment.
14. This Consent Agreement contemplates that, if the Commission accepts the Consent Agreement, the Commission thereafter may withdraw its acceptance of this Consent Agreement and notify Proposed Respondents, in which event the Commission will take such action as it may consider appropriate. If the Commission does not subsequently withdraw such acceptance pursuant to the provisions of Commission Rule 2.34, 16 C.F.R. § 2.34, and it has already issued the Complaint, the Commission may, without further notice to Proposed Respondents, issue the attached Decision and Order containing an order to divest and to provide for other relief in disposition of the proceeding.
15. The Decision and Order shall become final upon service. Delivery of the Complaint and the Decision and Order to Proposed Respondents by any means provided in Commission Rule 4.4(a), 16 C.F.R. § 4.4(a), or by delivery to United States counsel for Proposed Respondents identified in this Consent Agreement,

shall constitute service to Proposed Respondents. Proposed Respondents waive any rights they may have to any other manner of service. Proposed Respondents also waive any rights they may otherwise have to service of any appendices attached to or incorporated by reference into the Decision and Order, if Proposed Respondents are already in possession of such Appendices and agree that they are bound to comply with and will comply with the Decision and Order to the same extent as if they had been served with copies of the Appendices.

16. The Complaint may be used in construing the terms of the Decision and Order, and no agreement, understanding, representation, or interpretation not contained in the Decision and Order or the Consent Agreement may be used to vary or contradict the terms of the Decision and Order.
17. By signing this Consent Agreement, Proposed Respondents represent and warrant that:
 - a. they can fulfill all the terms of and accomplish the full relief contemplated by the Decision and Order, including, among other things, effectuating the required retention of assets, assignments, and transfers, and obtaining any necessary approvals from governmental authorities, leaseholders, and other third parties to effectuate the retention of assets, assignments, and transfers; and
 - b. all parents, subsidiaries, affiliates, and successors necessary to effectuate the full relief contemplated by this Consent Agreement and the Decision and Order, are parties to this Consent Agreement and are bound as if they had signed this Consent Agreement and were made parties to this proceeding or are within the control of parties to this Consent Agreement and the Decision and Order, or will be after the acquisition.
18. Proposed Respondents have read the Draft Complaint and the proposed Decision and Order. Proposed Respondents agree to comply with the terms of the proposed Decision and Order from the date they sign this Consent Agreement. Proposed Respondents understand that once the Commission has issued the Decision and Order, they will be required to file one or more compliance reports setting forth in detail the manner in which they have complied, have prepared to comply, are complying, and will comply with the Decision and Order. When final, the Decision and Order shall have the same force and effect and may be altered, modified, or set aside in the same manner and within the same time as provided by statute for other orders. Proposed Respondents further understand that they may be liable for civil penalties in the amount provided by law for each violation of the Decision and Order.

<p>Hikma Pharmaceuticals PLC</p> <hr/> <p>By: Sigurdur Olafsson Chief Executive Officer Hikma Pharmaceuticals PLC</p> <p>Dated: _____</p> <hr/> <p>Maria Raptis Skadden, Arps, Slate, Meagher & Flom LLP Counsel for Hikma Pharmaceuticals PLC</p> <p>Dated: _____</p> <p>Custopharm, Inc.</p> <hr/> <p>By: William Larkins Chief Executive Officer Custopharm, Inc.</p> <p>Dated: _____</p> <hr/> <p>Stephanie Greco Kirkland & Ellis LLP Counsel for Custopharm, Inc.</p> <p>Dated: _____</p>	<p>FEDERAL TRADE COMMISSION</p> <hr/> <p>By: Frances Anne Johnson Attorney Bureau of Competition</p> <hr/> <p>Peggy Bayer Femenella Acting Assistant Director Bureau of Competition</p> <hr/> <p>Tara Isa Koslov Deputy Director Bureau of Competition</p> <hr/> <p>Holly Vedova Director Bureau of Competition</p> <p>Dated: _____</p>
---	--

Water Street Healthcare Partners, LLC

By: Jeff Holway
Chief Administrative Officer
Water Street Healthcare Partners, LLC

Dated: _____

Stephanie Greco
Kirkland & Ellis LLP
Counsel for Water Street Healthcare Partners
LLC

Dated: _____

Water Street Healthcare Partners III, L.P.

By: Water Street Healthcare Management III,
L.P.
Its: General Partner

By: Water Street Healthcare Partners, LLC
Its: General Partner

By: Jeff Holway
Chief Administrative Officer

Dated: _____

Stephanie Greco
Kirkland & Ellis LLP
Counsel for Water Street Healthcare Partners
III, L.P.

Dated: _____

Water Street Healthcare Partners IV, L.P.

By: Water Street Healthcare IV, L.P.
Its: General Partner

By: Water Street Healthcare Partners, LLC
Its: General Partner

By: Jeff Holway
Chief Administrative Officer

Dated: _____

Stephanie Greco
Kirkland & Ellis LLP
Counsel for Water Street Healthcare Partners
IV, L.P.

Dated: _____

Long Grove Pharmaceuticals, LLC

By: Daniel S. Robins
Chief Executive Officer
Long Grove Pharmaceuticals, LLC

Dated: _____

Stephanie Greco
Kirkland & Ellis LLP
Counsel for Long Grove Pharmaceuticals, LLC

Dated: _____